Bayer Files $7.25 Billion Nationwide Roundup Settlement to End Glyphosate Claims
Bayer filed a $7.25 billion nationwide class settlement in St. Louis to resolve current and future Roundup glyphosate-cancer claims, paid over as long as 21 years.
By 411 Press Newsroom2 min read
Bayer AG, the parent company of Monsanto, has filed a $7.25 billion nationwide class settlement in Missouri state court in St. Louis, designed to resolve all current and future claims that its weedkiller Roundup causes cancer. The settlement would be paid out over as long as 21 years.
It is an attempt to draw a line under one of the largest product-liability fights in the country — litigation that has produced enormous jury verdicts, years of appeals, and persistent uncertainty for Bayer's investors and for the tens of thousands of people who say glyphosate exposure caused their non-Hodgkin lymphoma.
Why a "current and future" class settlement is the move
The recurring problem for Bayer has not been any single case — it is the open-ended exposure. As long as new plaintiffs can file, the liability never closes. A class settlement that covers future claimants is an effort to cap that tail: a defined fund, paid over decades, in exchange for resolving the litigation as a whole.
These structures are legally complex and often contested. Future-claims classes raise hard questions about whether people who are not yet sick — and have not yet hired a lawyer — can have their rights settled now, and courts scrutinize them closely. Approval is not automatic.
What it means for claimants
For people with pending Roundup claims, a settlement of this size signals movement after years of grinding litigation, but the terms — who qualifies, how much individual claimants receive, and how the fund is administered over a 21-year horizon — are what actually determine value. A large headline number spread across a very large class and two decades can mean modest individual recoveries.
411 Press covers mass-tort litigation as accountability news: who was harmed, what the science and the courts have concluded, and what a settlement does and doesn't deliver for the people it's meant to compensate.
What we're watching
- Whether the court preliminarily approves the class and on what terms
- Objections from plaintiffs' firms and individual claimants
- How the settlement treats future claimants versus those already filed
We'll follow the approval process as it unfolds.
Related coverage
